Biological Skin Graft With Keratinocyte-stem Cell Co-cultre for Burn Patients

NCT ID: NCT05652816

Last Updated: 2022-12-15

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Clinical Phase

EARLY_PHASE1

Total Enrollment

20 participants

Study Classification

INTERVENTIONAL

Study Start Date

2022-09-06

Study Completion Date

2024-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The goal of this clinical trial is to test whether artificial skin graft can substitute autologous skin graft in current burn treatment. The main question it aims to answer is:

• Can artificial skin graft result in better wound healing compared to the current burn treatment; autologous skin graft?

You will:

* Undergo debridement surgery
* Receive artificial skin graft as an alternative to autologous skin graft
* Undergo biopsy procedure of burn area

If there is a comparison group: Researchers will compare autologous skin graft group to see the wound healing process

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Burn caused by working accidents occurs mostly in the male population of productive age (68.68%). Up to this date, the only treatment for grade 2B-3 burns patients in Indonesia is skin transplantation taken from their own body (autologous skin graft). This treatment has several drawbacks in which repeated surgery is sometimes necessary, the source of skin in patients with wide area of burn is limited, and patients that are in the elder age and have comorbidities have high mortality risk.

In order to find an alternative for autologous skin graft therapy, a combination of tissue engineering and stem cell therapy is used to invent an artificial skin graft. The present study attempts to evaluate the efficacy of artificial skin graft seeded with autologous keratinocyte and stem cells towards wound healing in burn patients. The artificial graft used in this study is amnion bilayer; a graft that was decellularized to remove donor's cells and then layered to form into 3-D.

To evaluate the efficacy, biopsies are taken from the burn area of patients to evaluate the histoarchitecture of patients' tissue by histological staining (H\&E and Movat's pentachrome, IHC collagen I, collagen III, vWF, and alpha-SMA) and measure the relative gene expression by qPCR. For clinical data, burn area calculation using Rule of 9 method and thermography measurement using FLIRONE. Furthermore, systemic evaluation of patients are done by monitoring the procalcitonin, lactate, mean arterial pressure, gradation of wound, and sensory of burn area. The evaluation and measurement mentioned above are then compared to patients treated with the current available therapy; autologous skin graft. The artificial skin graft is hoped to result in equal, if not better, wound healing in burn patients compared to autologous skin graft. The investigators hope that artificial skin graft can be an option, other than autologous skin graft, in treating burn patients in the future.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Burn Degree Second Burn Degree Third

Keywords

Explore important study keywords that can help with search, categorization, and topic discovery.

artificial skin graft keratinocyte amnion epithelial stem cells burn

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

STSG (Split-Thickness Skin Graft)

Patients treated with the standard treatment; autologous skin graft

Group Type SHAM_COMPARATOR

Split-thickness skin graft

Intervention Type PROCEDURE

Transplantation of autologous skin to burn area

Amnion Bilayer Only

Patients treated with artificial graft only

Group Type EXPERIMENTAL

Artificial skin graft

Intervention Type BIOLOGICAL

Decellularized amnion membrane formed into 3-D matrix

Amnion Bilayer seeded with co-culture

Patients treated with artificial graft seeded with autologous keratinocyte co-cultured with amnion epithelial stem cells

Group Type EXPERIMENTAL

Artificial skin graft co-culture

Intervention Type BIOLOGICAL

Decellularized amnion membrane formed into 3-D matrix seeded with autologous keratinocyte co-cultured with amnion epithelial stem cells

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Split-thickness skin graft

Transplantation of autologous skin to burn area

Intervention Type PROCEDURE

Artificial skin graft

Decellularized amnion membrane formed into 3-D matrix

Intervention Type BIOLOGICAL

Artificial skin graft co-culture

Decellularized amnion membrane formed into 3-D matrix seeded with autologous keratinocyte co-cultured with amnion epithelial stem cells

Intervention Type BIOLOGICAL

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Aged 18 - 55
* Area of burn \<50%
* Acute phase burn (\<120 hrs)
* Have not undergo any surgery for burn treatment

Exclusion Criteria

* Immunocompromised
* Have comorbidities
Minimum Eligible Age

18 Years

Maximum Eligible Age

55 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Indonesia University

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

dr. Aditya Wardhana

Head of Burns Unit, Cipto Mangunkusumo National Hospital

Responsibility Role PRINCIPAL_INVESTIGATOR

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

RSUPN Cipto Mangunkusumo

Jakarta Pusat, DKI Jakarta, Indonesia

Site Status RECRUITING

Countries

Review the countries where the study has at least one active or historical site.

Indonesia

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

Aditya Wardhana, MD

Role: primary

Normalina Sandora, PhD

Role: backup

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

KET-866/ETIK/2021

Identifier Type: -

Identifier Source: org_study_id